152 related articles for article (PubMed ID: 36309821)
21. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
[TBL] [Abstract][Full Text] [Related]
22. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
[TBL] [Abstract][Full Text] [Related]
24. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
[TBL] [Abstract][Full Text] [Related]
25. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
[TBL] [Abstract][Full Text] [Related]
26. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Pratz KW; Cho E; Levis MJ; Karp JE; Gore SD; McDevitt M; Stine A; Zhao M; Baker SD; Carducci MA; Wright JJ; Rudek MA; Smith BD
Leukemia; 2010 Aug; 24(8):1437-44. PubMed ID: 20535150
[TBL] [Abstract][Full Text] [Related]
27. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
[TBL] [Abstract][Full Text] [Related]
30. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition.
Brattås MK; Hemsing AL; Rye KP; Hatfield KJ; Reikvam H
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499034
[TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors.
Jung SY; Yug JS; Clarke JM; Bauer TM; Keedy VL; Hwang S; Kim SJ; Chung EK; Lee JI
Cancer Chemother Pharmacol; 2020 Jan; 85(1):173-183. PubMed ID: 31673825
[TBL] [Abstract][Full Text] [Related]
33. Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W; Klisovic RB; Byrd JC; Garzon R; Baker SD; Bhatnagar B
Invest New Drugs; 2020 Apr; 38(2):340-349. PubMed ID: 31102119
[TBL] [Abstract][Full Text] [Related]
34. FLT3 inhibitors in acute myeloid leukemia: Current and future.
Thomas CM; Campbell P
J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754
[TBL] [Abstract][Full Text] [Related]
35. Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Elgamal OA; Mehmood A; Jeon JY; Carmichael B; Lehman A; Orwick SJ; Truxall J; Goettl VM; Wasmuth R; Tran M; Mitchell S; Lapalombella R; Eathiraj S; Schwartz B; Stegmaier K; Baker SD; Hertlein E; Byrd JC
J Hematol Oncol; 2020 Jan; 13(1):8. PubMed ID: 31992353
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
DeAngelo DJ; Stone RM; Heaney ML; Nimer SD; Paquette RL; Klisovic RB; Caligiuri MA; Cooper MR; Lecerf JM; Karol MD; Sheng S; Holford N; Curtin PT; Druker BJ; Heinrich MC
Blood; 2006 Dec; 108(12):3674-81. PubMed ID: 16902153
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer.
Bonate PL; Cunningham CC; Gaynon P; Jeha S; Kadota R; Lam GN; Razzouk B; Rytting M; Steinherz P; Weitman S
Cancer Chemother Pharmacol; 2011 Apr; 67(4):875-90. PubMed ID: 20582417
[TBL] [Abstract][Full Text] [Related]
38. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
[TBL] [Abstract][Full Text] [Related]
40. SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Puissant A; Fenouille N; Alexe G; Pikman Y; Bassil CF; Mehta S; Du J; Kazi JU; Luciano F; Rönnstrand L; Kung AL; Aster JC; Galinsky I; Stone RM; DeAngelo DJ; Hemann MT; Stegmaier K
Cancer Cell; 2014 Feb; 25(2):226-42. PubMed ID: 24525236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
